Linda JW Bosch
机构: Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands
主页: linkedin.com
每年引用次数
引用次数
引用: 1,807
H-指数: 20
I10-指数 : 32
出版物: 92
Unbiased and UMI-informed sequencing of cell-free miRNAs at single-nucleotide resolution
Hackenberg M , Pegtel D , Aparicio-Puerta E , Scheepbouwer C
bioRxiv
2021
Basic fibroblast growth factor-mediated overexpression of vascular endothelial growth factor in 1F6 human melanoma cells is regulated by activation of PI-3K and p38 MAPK
Maria P. A. van Berkel , Linda J. W. Bosch , Epie Boven , Monique C. A. Duyndam
Analytical Cellular Pathology 31 ( 3) 179 -190
5
2009
Analytical sensitivity and stability of DNA methylation testing in stool samples for colorectal cancer detection.
Linda J. W. Bosch , Sandra Mongera , Jochim S. Terhaar sive Droste , Frank A. Oort
Cellular Oncology 35 ( 4) 309 -315
24
2012
Fecal Tests: From Blood to Molecular Markers
Graeme P. Young , Linda J. W. Bosch
Current Colorectal Cancer Reports 7 ( 1) 62 -70
19
2011
Study protocol: Whole genome sequencing Implementation in standard Diagnostics for Every cancer patient (WIDE).
Kris G. Samsom , Linda J. W. Bosch , Luuk J. Schipper , Paul Roepman
BMC Medical Genomics 13 ( 1) 169 -169
6
2020
Aurora kinase A (AURKA) interaction with Wnt and Ras-MAPK signalling pathways in colorectal cancer
Annika Jacobsen , Linda J. W. Bosch , Sanne R. Martens-de Kemp , Beatriz Carvalho
Scientific Reports 8 ( 1) 7522 -7522
11
2018
Genomic landscape of metastatic colorectal cancer
Josien C. Haan , Mariette Labots , Christian Rausch , Miriam Koopman
Nature Communications 5 ( 1) 5457 -5457
49
2014
Molecular markers for colorectal cancer screening and prediction of response to therapy
L.J.W. Bosch
Amsterdam: Vrije Universiteit
2013
Methylering, een veelbelovende biomarker voor het opsporenvan tumoren in lichaamsvloeistoffen
P.J. van Diest , L.J.W. Bosch , B. Carvalho , E. van der Wall
Kanker Breed 5 ( 1) 24 -27
2013
Identification of biological axes associated with stage II/III CRC recurrence risk and outcome after adjuvant therapy revealed a T-effector-independent prognostic role for granzyme B
M. Das Thakur , A. Udyavar , T. Sandmann , C. Li
Annals of Oncology 29
2018
Multitarget Stool DNA Test Performance in an Average-Risk Colorectal Cancer Screening Population
L.J.W. Bosch , V. Melotte , S. Mongera , K.L.J. Daenen
The American Journal of Gastroenterology 114 ( 12) 1909 -1918
15
2019
Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers.
P. Snaebjornsson , D.A.M. Heideman , N.C.T. van Grieken , L.J.W. Bosch
International Journal of Cancer 138 ( 5) 1139 -1145
24
2016
Molecular markers and the future of colorectal cancer screening
Beatriz Carvalho , Linda JW Bosch , Manon Van Engeland , Gerrit A Meijer
Colorectal cancer 2 ( 2) 95 -97
2013
Consensus molecular subtype classification of colorectal adenomas
Malgorzata A Komor , Linda JW Bosch , Gergana Bounova , Anne S Bolijn
The Journal of Pathology 246 ( 3) 266 -276
19
2018
Proteins in stool as biomarkers for non-invasive detection of colorectal adenomas with high risk of progression.
Sandra Mongera , Chris JJ Mulder , Evelien Dekker , Ernst J Kuipers
The Journal of Pathology 250 ( 3) 288 -298
25
2020
Transcriptomic profiling of adjuvant colorectal cancer identifies three key prognostic biological processes and a disease specific role for granzyme B
Anneleen Daemen , Akshata R Udyavar , Thomas Sandmann , Congfen Li
Plos one 16 ( 12) e0262198 -e0262198
3
2021
Novel stool-based protein biomarkers for improved colorectal cancer screening: a case–control study
Linda JW Bosch , Meike De Wit , Thang V Pham , Veerle MH Coupé
Annals of Internal Medicine 167 ( 12) 855 -866
55
2017
Promoter CpG island hypermethylation of Decoy Receptor 1 (DCR1) is associated with poor response to irinotecan in colorectal cancer.
Linda JW Bosch , Geert Trooskens , Petur Snaebjornsson , Josien C Haan
Cancer Research 73 ( 8_Supplement) 1155 -1155
1
2013
DNA methylation and gene expression at chromosomal loci with copy number gain in colorectal cancer
Linda JW Bosch , Geert Trooskens , Tim de Meyer , Evert van den Broek
The interferon-gamma (IFN-y) signature from baseline tumor material predicts pathologic response after neoadjuvant ipilimumab (IPI)+ nivolumab (NIVO) in stage III melanoma.
Irene LM Reijers , Petros Dimitriadis , Elisa A Rozeman , Oscar Krijgsman
Journal of Clinical Oncology 40 ( 16_suppl) 9539 -9539
9
2022